The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Type of residual symptom and risk of relapse during the continuation/maintenance phase treatment of major depressive disorder with the selective serotonin reuptake inhibitor fluoxetine
Abstract
Unlabelled Relapse of major depressive disorder (MDD) is a common clinical problem. Identifying relapse predictors could lead to strategies that reduce relapse risk. This study is designed to determine whether residual symptoms predict relapse risk during the continuation/maintenance treatment of MDD. 570 MDD patients received open-label fluoxetine for 12 weeks. Under double blind conditions, 262 patients who responded by week 12 were randomly assigned to continue fluoxetine or switch to placebo for 52 weeks or until relapse. Residual symptoms were measured using the Symptom Checklist-90 and the Symptom Questionnaire. The relationship between residual symptom severity and relapse risk was assessed. Without adjusting for overall residual symptom severity, a greater severity of residual obsessive-compulsive and phobic anxiety symptoms predicted greater relapse risk. After adjusting for overall residual symptom severity, only severity of phobic anxiety symptoms predicted relapse risk. The predictive value of phobic anxiety symptoms with respect to relapse risk was independent of treatment assignment. The results indicated that there may be a specific pattern of residual symptoms associated with depressive relapse during antidepressant continuation/maintenance, which is unrelated to treatment assignment. Future studies are needed to further explore the relationship between residual symptoms and relapse risk in MDD. Clinical implications (1) It is important to treat residual symptoms among antidepressant responders/remitters in order to decrease relapse risk. (2) Clinicians should target residual phobic anxiety symptoms in order to decrease relapse risk. (3) Clinicians should target residual obsessive-compulsive symptoms in order to decrease relapse risk. Limitations (1) limited generalizability due to inclusion/exclusion criteria; (2) lack of active comparator treatment group; (3) post hoc analysis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Phobic anxiety failed to yield significant interaction results.
“Analyses in a further study investigating specific residual symptoms, namely phobic anxiety, also failed to yield significant results (Yang et al. 2009).”
From Predicting relapse after antidepressant withdrawal – a systematic review (2017) · cites this paper as Yang et al. 2009
Citations
Cites
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643 · cited 2×
“Finally, in a more recent study, Rush et al. (2006) reported that patients in the STAR*D study who were in remission were less likely to experience a subsequent depressive relapse than patients who had only responded to their treatments [ 9 ].”
Self-citationECDEU Assessment Manual: (591322011-001)
Guy, W. (1976) · PsycEXTRA Dataset · doi:10.1037/e591322011-001 · Cited by 1,896
Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review
Geddes, J. R., Carney, S. M., Davies, C., Furukawa, T. A., Kupfer, D. J., Frank, E., & Goodwin, G. M. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12599-8 · Cited by 945 · cited 1×
“experience remission following successful treatment with antidepressants will relapse, despite continued treatment [3].”
InfluentialJudd, L. L., Schettler, P. J., Akiskal, H. S., Coryell, W., Leon, A. C., Maser, J. D., & Solomon, D. A. (2008) · Archives of General Psychiatry · doi:10.1001/archpsyc.65.4.386 · Cited by 251
Flagged first, then by citations
Research works printed but not linked: 12
- Kessler R, Berglund P, Demler O et al (2003) The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 289(23):3095–3105 · DOI · Paper page
- Trivedi M, Rush A, Wisniewski S et al (2006) Evaluation of outcomes with Citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 163:28–40 · DOI · Paper page
- Paykel E, Ramana R, Cooper Z et al (1995) Residual symptoms after partial remission: an important outcome in depression. Psychol Med 25(6):1171–1180 · DOI · Paper page
- Kennedy N, Paykel E (2004) Residual symptoms at remission from depression: impact on long-term outcome. J Affect Disord 80:135–144 · DOI · Paper page
- Judd L, Akiskal H, Maser J et al (1998) Major depressive disorder: a prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse. J Affect Disord 50:97–108 · DOI · Paper page
- Judd L, Paulus M, Schettler P et al (2000) Does incomplete recovery from first lifetime major depressive episode herald a chronic course of illness? Am J Psychiatry 157:1501–1504 · DOI · Paper page
- Dombrovski A, Mulsant B, Houck P et al (2007) Residual symptoms and recurrence during maintenance treatment of late life depression. J Affect Disord 103:77–82 · DOI
- McGrath P, Stewart J, Quitkin F et al (2006) Predictors of relapse in a prospective study of fluoxetine treatment of major depression. Am J Psychiatry 163:1542–1548 · DOI · Paper page
- First M, Spitzer R, Gibbon M et al (1995) Structured clinical interview for DSM-IV axis I disorders-Patient Edition (SCID-I/P, Version 2.0). In: Biometrics Research Department, New York State Psychiatric Institute, New York · DOI · Paper page
- Kellner R (1987) A symptom questionnaire. J Clin Psychiatry 48:268–274
- Derogatis L, Lipman R, Rickels K et al (1974) The Hopkins symptom checklist (HSCL): a self-report symptom inventory. J Appl Behav Sci 19:1–15
- Hamilton M (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56–62 · DOI · Paper page
Cited by
Sorted by citations
Predicting relapse after antidepressant withdrawal – a systematic review
Berwian, I. M., Walter, H., Seifritz, E., & Huys, Q. J. M. (2017) · Psychological Medicine · doi:10.1017/s0033291716002580 · Cited by 93
“Analyses in a further study investigating specific residual symptoms, namely phobic anxiety, also failed to yield significant results (Yang et al. 2009).”
ResultClevenger, S. S., Malhotra, D., Dang, J., Vanle, B., & IsHak, W. W. (2018) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125317737264 · Cited by 83
Saragoussi, D., Touya, M., Haro, J. M., Jönsson, B., Knapp, M., Botrel, B., Florea, I., Loft, H., & Rive, B. (2017) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s136343 · Cited by 63
Psychological Well-Being in Remitted Patients with Recurrent Depression
Risch, A. K., Taeger, S., Brüdern, J., & Stangier, U. (2013) · Psychotherapy and Psychosomatics · doi:10.1159/000351808 · Cited by 12
Metadata
- Authors
- Yang, H., Chuzi, S., Sinicropi-Yao, L., Johnson, D., Chen, Y., Clain, A., Baer, L., McGrath, P. J., Stewart, J. W., Fava, M., & Papakostas, G. I.
- Affiliations
- Harvard University (US)
- New York State Psychiatric Institute (US)
- Corresponding author
- Yang, Huaiyu
- Venue
- European Archives of Psychiatry and Clinical Neuroscience
- Published
- 2009-07-02
- Volume
- 260
- Issue
- 2
- Pages
- 145-150
- ISSN
- 0003-9373 (ISSN-L)
- 0940-1334
- 1433-8491
- OpenAlex
- W2082302379
- Cited by
- 42
- References
- 4
- Citations by year
- 2026: 2 · 2024: 3 · 2022: 5 · 2021: 4 · 2020: 2 · 2019: 2 · 2018: 2 · 2017: 3 · 2016: 1 · 2015: 1 · 2014: 2 · 2013: 4 · 2012: 1
- FWCI
- 2.64
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- European Archives of Psychiatry and Clinical Neuroscience (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Keywords
- major depressive disorder, relapse risk, residual symptoms, fluoxetine, phobic anxiety, obsessive-compulsive symptoms, recurrence prediction, antidepressant response
- MeSH terms
- Adolescent, Adult, Aged, Depressive Disorder, Major, Major Depressive Disorder, Double-Blind Method, Drug Administration Schedule, Female, Fluoxetine, Follow-Up Studies, Humans, Male, Middle Aged, Obsessive-Compulsive Disorder, Phobic Disorders, Predictive Value of Tests, Psychiatric Status Rating Scales, Surveys and Questionnaires, Risk Factors, Severity of Illness Index, Treatment Outcome, Selective Serotonin Reuptake Inhibitors, Secondary Prevention, Young Adult, Checklist
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
